# β-alanine in the Treatment of Advanced Hepatocellular Carcinoma

> **NCT07317414** · PHASE2 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 158 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Atezolizumab combined with bevacizumab combined with β- alanine
- **DRUG:** Atezolizumab combined with bevacizumab

## Key facts

- **NCT ID:** NCT07317414
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-24
- **Primary completion:** 2028-12-05
- **Final completion:** 2030-12-05
- **Target enrollment:** 158 (ESTIMATED)
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07317414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07317414, "β-alanine in the Treatment of Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07317414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*